China evaluating investigations into pharma firms to take on drug pricing issue

pharmafile | May 9, 2016 | News story | Business Services, Research and Development, Sales and Marketing China, France, G7, regulation 

Lawmakers globally have acknowledged the concerns over unbridled drug costs as regulators stress the need for a more open debate with the pharma industry.

Joining the pack is China, where the regulators are reportedly set to launch anti-trust investigations against pharma firms. The reports suggest the government plans a large-scale and systematic scrutiny into drugmakers both foreign and domestic.

The National Development and Reform Commission is gathering proof to establish if these pharma firms were in violation of guidelines pertaining to competition.

The news come close on the heels of reports France is looking at proposing joint action against drug pricing at the upcoming G7 meet.

Bottom-lines for drugmakers have taken a hit since China took to making its public healthcare system affordable.   

Anjali Shukla

Related Content

First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China

Boan Biotech has announced that the first patient has been enrolled in its phase 3 …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk …

Latest content